March 27, 2014

RuiYi Announces $15 Million Series B to Advance Pipeline of Therapeutic Monoclonal Antibodies Targeting GPCR Receptors

Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi’s iCAPS platfrom

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA. RuiYi has a pipeline of innovative monoclonal antibodies to previously untargeted G protein coupled receptors (GPCRs) for important global, therapeutic needs. The financing will support the continued development of RuiYi's lead asset, RYI-008, a novel anti-IL-6 monoclonal antibody (mAb), and the discovery and development of new therapeutic mAbs targeting GPCRs, including a first-in-class mAb to cannabinoid receptor 1 (CB-1), a commercially validated but previously intractable drug target. In addition, RuiYi expanded the leadership team, appointing Erik Karrer, Ph.D. as chief scientific officer and Brian Campion, Ph.D. as vice president of business development.
PDF Download

read more »

March 21, 2014

Biotie to regain global rights to tozadenant from UCB

• Tozadenant is transitioning into Phase 3 development for Parkinson's disease • Biotie to host a conference call for analysts and media today at 14:00 Central European time

Biotie Therapies Corp. announced today that UCB Pharma S.A. (UCB) will return global rights to tozadenant to Biotie. Tozadenant (SYN115), a selective inhibitor of the adenosine 2a (A2a) receptor, has delivered clinically relevant and statistically highly significant effects in Parkinson's disease, across multiple pre-specified evaluation parameters, in a 420 patient Phase 2b study completed in December 2012. Tozadenant is expected to start recruitment for the Phase 3 program in H1 2015.
PDF Download

read more »

March 12, 2014

Novimmune appoints Andrew J. Oakley as CFO

Novimmune SA announced today that Andrew J. Oakley has joined the company as Chief Financial Officer.
PDF Download

read more »

February 26, 2014

Evolva successfully places new shares

Evolva Holding SA (SIX: EVE, “Evolva” or the “Company”) has successfully completed its placement of shares which was announced yesterday. Evolva has sold 27,000,000 new shares via an accelerated bookbuild process by way of a private placement in Switzerland and outside of Switzerland in accordance with applicable securities laws. The shares have been placed at a price of CHF 1.37 per share, representing a discount of 4.9% to the closing price of 25 February 2014.
PDF Download - English Version
PDF Download - German Version

read more »

February 25, 2014

Evolva reports preliminary, unaudited financial results for 2013 and announces launch of share placement

Evolva Holding SA (SIX: EVE, “Evolva” or the “Company”) today announces its preliminary, unaudited financial results for 2013. In 2013, the Company had total revenues of CHF 8.7 million compared with CHF 7.0 million in 2012 and generated an operational loss of CHF 17.7 million (2012: CHF 20.0 million). The cash outflow from operations and investment amounted to CHF 13.6 million (2012: CHF 14.0 million). At the end of 2013, the Company had CHF 29.3 million in cash and cash equivalents. Each of these parameters is within the guidance provided in August 2013. The audited financial report for 2013 will be released on 8 April 2014, as previously announced.
PDF Download - English Version
PDF Download - German Version
 

read more »

February 18, 2014

Novimmune announces closing of CHF 60 million financing

Novimmune SA announced that it has closed a Series B financing for CHF 60 million ($66 million). London-based Rosetta Capital Limited led the round with participation of new private investors as well as existing investors.
PDF Download

read more »

February 18, 2014

SynAffix raises Series A investment round to advance its GlycoConnect™ technology for creating next-generation ADCs

SynAffix B.V., a protein engineering company focusing on the creation of next-generation Antibody-Drug Conjugates (ADCs), today announced the completion of its Series A investment round. Financial details have not been disclosed.
PDF Download

read more »

February 13, 2014

EBM and ewb increase wind energy production

EBM and Energie Wasser Bern (ewb) continue to expand their share of energy production from renewable sources. Through their joint venture company "leading swiss renewables AG" (LSR) and with the support of Aravis they have acquired two French wind parks with a total capacity of 18 Megawatts (MW).
PDF Download - English Version
PDF Download - German Version

read more »

February 10, 2014

Evolva announces collaboration with L’Oréal

Evolva Holding SA (SIX: EVE) announced that it has signed a collaboration agreement with L’Oréal for the co-development of novel biosynthetic production routes for an undisclosed ingredient with broad applications in the cosmetics industry. Evolva and L’Oréal will apply Evolva’s fermentation technology platform to develop and optimise yeast strains for the sustainable, cost-effective production of this strategically important cosmetics ingredient.
PDF Downloan - English Version
PDF Download - German Version

read more »

January 09, 2014

ARAVIS strengthens life science team with three important appointments

Dr Dani Bach (formerly of Index Ventures) joins as Managing Partner, Dr Jacques Mizrahi joins in a consulting role as Venture Partner and Kadri Vunder (formerly LSVenture) as a Partner

Aravis, the first independent Swiss on-shore private equity house and an established investor in the life science and renewable energy spaces, today announced the appointment of three new members of the life science investment team.
PDF Download

read more »